Aortic Valve StenosisNCT02146755
Improving Echo Measurements in the Diagnosis of Aortic Stenosis
An observational study of Aortic Valve Stenosis, run by Baylor Research Institute at 2 sites in United States.
Trial summary
Aortic stenosis is a common valvular heart disease, affecting mainly people over age 60. It is characterized by years to decades of slow progression followed by rapid clinical deterioration and a high death rate once symptoms develop. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Aortic Valve Stenosis
- How many people
- 396 participants
- Where
- 2 sitesUnited States
- Study dates
- Aug 2013to Dec 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study is an observational, retrospective review of data collected as standard of care. The study intends to review the charts of up to 400 patients over the last 5 years who underwent both CT and TTE within a one-week timeframe as a workup for aortic valve stenosis at The Heart Hospital Baylor Plano (THHBP) or Baylor University Medical Center (BUMC).
Who may be able to join
- Adults over the age of 18.
- Any patient undergoing both TTE and CT scans within a one-week timeframe as a workup for aortic stenosis.
Who cannot join
- There are no specific exclusion criteria for this retrospective review.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Baylor University Medical Center at Dallas
Dallas, Texas, 75246
Heart Hospital Baylor Plano
Plano, Texas, 75093
About this study
Official title: Improving The Quality Of Echocardiographic Imaging Measurements In The Diagnosis Of Severe Aortic Stenosis
Aortic stenosis is a common valvular heart disease, affecting mainly people over age 60. It is characterized by years to decades of slow progression followed by rapid clinical deterioration and a high death rate once symptoms develop. The onset of symptoms confers a poor prognosis: patients die within an average of five years after the onset of angina, three years after the onset of syncope, and two years after the onset of heart failure symptoms. The overall mortality rate is 75% at three years without surgery. Drug therapy for it remains ineffective, and aortic valve replacement is the only recommended long-term treatment.
Read the detailed description
OBJECTIVES Primary Objective The primary objective of this study is to review the current practice of transthoracic echocardiogram (TTE) imaging measurements in conjunction with computerized tomography (CT) and to standardize these measurements in order to improve the accuracy of the diagnosis of aortic stenosis (AS).
Secondary Objective The secondary objective of the study is to define the true incidence of low flow, low gradient severe aortic stenosis with a normal ejection fraction (EF).
BACKGROUND In recent years, the advancement of medical technology has allowed certain patients to undergo less invasive approaches for aortic valve replacement such as transcatheter aortic valve replacement (TAVR). In order to appropriately select treatment options, anatomical measurements must be accurately obtained utilizing TTE and CT.
According to the American College of Cardiology/American Heart Association Practice Guidelines, the severity o f aortic stenosis is determined by definitions of aortic jet velocity, mean pressure gradient, and aortic valve area (AVA) (Bonow, 2008).
Mild Moderate Severe AVA (cm2) 1.5 1.0 - 1.5 < 1.0 Mean gradient (mmHg) < 25 25 - 40 > 40 Jet velocity (m/s) < 3.0 3.0 - 4.0 > 4.0
Rationale for study
Of greatest interest to this study is the calculation of the AVA in the diagnosis of the severity of aortic stenosis. Since the area cannot be directly measured from echocardiographic images, it is calculated based on the diameter across the left ventricular outflow tract (LVOT) as measured via TTE. The preferred modality for measuring AVA is the continuity equation:
AVA=((〖Area〗_LVOT ×〖VTI〗_LVOT))/〖VTI〗_AS Where LVOT = Left Ventricular Outflow Tract, VTI = Doppler velocity-time interval.
Using TTE, the stroke volume at the LVOT is obtained by measuring the diameter across the LVOT. The continuity equation assumes the aortic valve annulus is a perfect circle; because of this, any error in measuring the LVOT results in an under calculation of the aortic valve area. It is also important to consider that the anatomy of the aortic annulus is not circular, which also contributes to an inaccurate calculated AVA.
An underestimated valve area could lead to a diagnosis of severe aortic stenosis when not appropriate. Recently, there has been an increase in literature published on the diagnosis of severe aortic stenosis with a low mean gradient and preserved left ventricular function as measured by ejection fraction (EF). It is possible that many of these patients do not have severe AS but are misclassified as such because underestimation of the LVOT diameter leads to underestimation of aortic valve area as calculated by the continuity equation. This study aims to define the true incidence of these patients by ensuring the aortic valve area is measured as accurately as possible based on current imaging procedures.
In order to determine the accuracy of TTE measurements in current practice, this study would compare the LVOT diameter from TTE to the LVOT diameter on CT scans, which is inherently three-dimensional and therefore more accurate.
The AVA of all subjects will be re-calculated using the continuity equation and the LVOT diameter measured with CT. These re-calculated AVA will be compared to the original AVA obtained via TTE. In subjects whose newly calculated AVA, utilizing CT measurements, varies greatly from their TTE calculated AVA, the original TTE images will be re-evaluated for correct measurements. Additionally, any subject with a TTE-measured LVOT diameter less than 2 cm will also be re-evaluated for correct measurement.
The figure below illustrates an underestimated LVOT diameter using 2D echocardiography.
Anumeha Tandon, Paul A. Grayburn, Imaging of Low-Gradient Severe Aortic Stenosis, JACC: Cardiovascular Imaging, Volume 6, Issue 2, February 2013, Pages 184-195, ISSN 1936-878X, http://dx.doi.org/10.1016/j.jcmg.2012.11.005.
(http://www.sciencedirect.com/science/article/pii/S1936878X12009497)
PATIENT POPULATION
This study is an observational, retrospective review of data collected as standard of care. The study intends to review the charts of up to 400 patients over the last 5 years who underwent both CT and TTE within a one-week timeframe as a workup for aortic valve stenosis at The Heart Hospital Baylor Plano (THHBP) or Baylor University Medical Center (BUMC).
SUMMARY Enrollment Up to 400 patients at THHBP and BUMC Design This study is a retrospective chart review of previously collected standard of care data.
METHODS, STATISTICAL ANALYSIS \& DATA MANAGEMENT Patients will be classified as severe or non-severe AS based on aortic valve area calculation as per ACC/AHA guidelines. Thus, patients with AVA ≤ 1.0 cm2 will be considered severe AS. This will also be evaluated using two other widely used criteria for aortic valve area indexed for body surface area. Severe AS will be considered as AVAi ≤ 0.6 cm2 (guidelines) or ≤ 0.5 cm2 (Braunwald's text, Grayburn). Using these three definitions, any patient who also has a peak velocity ≥ 4.0 m/s or a mean gradient ≥ 40 mmHg will be considered to definitely have severe AS. Patients with values < 4.0 m/s or < 50 mmHg will be further classified by stroke volume index < 35 mL/m2 to have low flow, low gradient severe AS. Further classification will be based on LVEF ≥ 50% or <50%. The former will be considered to have paradoxical low flow, low gradient severe AS with preserved LVEF (Hachicha, Circ 2007) or traditional low flow, low gradient severe AS (Tandon, Grayburn JACC Imaging 20130> The above criteria will be used to reclassify patients when LVOT cross-sectional area is determined by CT scan instead of echocardiography. Reclassification will occur with CT measurements of LVOT for AVA and SVI, both of which are dependent on LVOT area, generalized linear mixed model (GLMM) with a logistic link function will be used to assess whether differences in classification exist.
The same multivariable model stratified by gender will be used to perform a pre-specified subgroup analysis (re-measuring the echocardiographic LVOT diameter on all subjects who are "re-classified" by CT). This will be done by remeasuring at the traditional LVOT diameter located 5-10 mm below the aortic annulus and also by measuring at the juncture of the aortic leaflets and LVOT in mid-systole (Mayo clinic way). The purpose of this analysis is to determine if the Mayo clinic method of LVOT measurement reduces the number of misclassifications compared to the traditional method. Finally, the investigators will also examine the CT data for threshold values which suggest erroneous or outlier values for echocardiography. Men and women will be assessed separately. For example, a value of 1.6 cm is often found on echocardiography but rarely on CT scanning in their subjective clinical experience.
- Conditions
- Aortic Valve Stenosis
- Medical subject headings
- Aortic Valve Stenosis
What is being measured
The primary outcome is the main question the study is designed to answer.
Reclassification of patients based on CT measurements of LVOT for AVA and SVI.
Echocardiography assessments of Aortic stenosis are technician dependent and can vary while CT evaluations are consistent and do not vary by user. This study will retrospectively examine subjects that have undergone both assessments as a workup for definitive aortic valve treatment. The anatomical measurements obtained from CT will be used to recalculate Aortic Valve Area utilizing the standard formulas and gradients/velocities obtained from echocardiography. Patients will be reclassified appropriately into "severe and non-severe" AS according to the new calculations. The results of this will be analyzed to establish standardized ranges for measurements to prevent over or under measuring aortic valve anatomy during these tests (Echo and CT).
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2014 (estimated)
- Study startAug 2013
- Primary completionDec 2015
- Study completionDec 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aortic Valve StenosisStudies of the same condition, open and under way.
- More trials run by Baylor Research InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 396 participants (actual)
Sponsor and investigators
- Lead sponsor
- Baylor Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Paul Grayburn, MD, Principal investigator, Baylor Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02146755
- Sponsor's protocol ID
- 013-178
- Status last verified
- Jun 2017
- First submitted
- 10 Apr 2014
- Last updated
- 12 Jun 2017
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving The Quality Of Echocardiographic Imaging Measurements In The Diagnosis Of Severe Aortic Stenosis
- ClinicalTrials.gov ID
- NCT02146755
- Acronym / sponsor ID
- 013-178
- Conditions
- Aortic Valve Stenosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 396 participants (actual)
- Lead sponsor
- Baylor Research InstituteUniversity, hospital or other
- Study start
- Aug 2013
- Primary completion
- Dec 2015 (actual)
- Study completion
- Dec 2015 (actual)
- First posted
- 26 May 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aortic stenosis is a common valvular heart disease, affecting mainly people over age 60. It is characterized by years to decades of slow progression followed by rapid clinical deterioration and a high death rate once symptoms develop. The onset of symptoms confers a poor prognosis: patients die within an average of five years after the onset of angina, three years after the onset of syncope, and two years after the onset of heart failure symptoms. The overall mortality rate is 75% at three years without surgery. Drug therapy for it remains ineffective, and aortic valve replacement is the only recommended long-term treatment.
Detailed description
OBJECTIVES Primary Objective The primary objective of this study is to review the current practice of transthoracic echocardiogram (TTE) imaging measurements in conjunction with computerized tomography (CT) and to standardize these measurements in order to improve the accuracy of the diagnosis of aortic stenosis (AS).
Secondary Objective The secondary objective of the study is to define the true incidence of low flow, low gradient severe aortic stenosis with a normal ejection fraction (EF).
BACKGROUND In recent years, the advancement of medical technology has allowed certain patients to undergo less invasive approaches for aortic valve replacement such as transcatheter aortic valve replacement (TAVR). In order to appropriately select treatment options, anatomical measurements must be accurately obtained utilizing TTE and CT.
According to the American College of Cardiology/American Heart Association Practice Guidelines, the severity o f aortic stenosis is determined by definitions of aortic jet velocity, mean pressure gradient, and aortic valve area (AVA) (Bonow, 2008).
Mild Moderate Severe AVA (cm2) 1.5 1.0 - 1.5 < 1.0 Mean gradient (mmHg) < 25 25 - 40 > 40 Jet velocity (m/s) < 3.0 3.0 - 4.0 > 4.0
Rationale for study
Of greatest interest to this study is the calculation of the AVA in the diagnosis of the severity of aortic stenosis. Since the area cannot be directly measured from echocardiographic images, it is calculated based on the diameter across the left ventricular outflow tract (LVOT) as measured via TTE. The preferred modality for measuring AVA is the continuity equation:
AVA=((〖Area〗_LVOT ×〖VTI〗_LVOT))/〖VTI〗_AS Where LVOT = Left Ventricular Outflow Tract, VTI = Doppler velocity-time interval.
Using TTE, the stroke volume at the LVOT is obtained by measuring the diameter across the LVOT. The continuity equation assumes the aortic valve annulus is a perfect circle; because of this, any error in measuring the LVOT results in an under calculation of the aortic valve area. It is also important to consider that the anatomy of the aortic annulus is not circular, which also contributes to an inaccurate calculated AVA.
An underestimated valve area could lead to a diagnosis of severe aortic stenosis when not appropriate. Recently, there has been an increase in literature published on the diagnosis of severe aortic stenosis with a low mean gradient and preserved left ventricular function as measured by ejection fraction (EF). It is possible that many of these patients do not have severe AS but are misclassified as such because underestimation of the LVOT diameter leads to underestimation of aortic valve area as calculated by the continuity equation. This study aims to define the true incidence of these patients by ensuring the aortic valve area is measured as accurately as possible based on current imaging procedures.
In order to determine the accuracy of TTE measurements in current practice, this study would compare the LVOT diameter from TTE to the LVOT diameter on CT scans, which is inherently three-dimensional and therefore more accurate.
The AVA of all subjects will be re-calculated using the continuity equation and the LVOT diameter measured with CT. These re-calculated AVA will be compared to the original AVA obtained via TTE. In subjects whose newly calculated AVA, utilizing CT measurements, varies greatly from their TTE calculated AVA, the original TTE images will be re-evaluated for correct measurements. Additionally, any subject with a TTE-measured LVOT diameter less than 2 cm will also be re-evaluated for correct measurement.
The figure below illustrates an underestimated LVOT diameter using 2D echocardiography.
Anumeha Tandon, Paul A. Grayburn, Imaging of Low-Gradient Severe Aortic Stenosis, JACC: Cardiovascular Imaging, Volume 6, Issue 2, February 2013, Pages 184-195, ISSN 1936-878X, http://dx.doi.org/10.1016/j.jcmg.2012.11.005.
(http://www.sciencedirect.com/science/article/pii/S1936878X12009497)
PATIENT POPULATION
This study is an observational, retrospective review of data collected as standard of care. The study intends to review the charts of up to 400 patients over the last 5 years who underwent both CT and TTE within a one-week timeframe as a workup for aortic valve stenosis at The Heart Hospital Baylor Plano (THHBP) or Baylor University Medical Center (BUMC).
SUMMARY Enrollment Up to 400 patients at THHBP and BUMC Design This study is a retrospective chart review of previously collected standard of care data.
METHODS, STATISTICAL ANALYSIS \& DATA MANAGEMENT Patients will be classified as severe or non-severe AS based on aortic valve area calculation as per ACC/AHA guidelines. Thus, patients with AVA ≤ 1.0 cm2 will be considered severe AS. This will also be evaluated using two other widely used criteria for aortic valve area indexed for body surface area. Severe AS will be considered as AVAi ≤ 0.6 cm2 (guidelines) or ≤ 0.5 cm2 (Braunwald's text, Grayburn). Using these three definitions, any patient who also has a peak velocity ≥ 4.0 m/s or a mean gradient ≥ 40 mmHg will be considered to definitely have severe AS. Patients with values < 4.0 m/s or < 50 mmHg will be further classified by stroke volume index < 35 mL/m2 to have low flow, low gradient severe AS. Further classification will be based on LVEF ≥ 50% or <50%. The former will be considered to have paradoxical low flow, low gradient severe AS with preserved LVEF (Hachicha, Circ 2007) or traditional low flow, low gradient severe AS (Tandon, Grayburn JACC Imaging 20130> The above criteria will be used to reclassify patients when LVOT cross-sectional area is determined by CT scan instead of echocardiography. Reclassification will occur with CT measurements of LVOT for AVA and SVI, both of which are dependent on LVOT area, generalized linear mixed model (GLMM) with a logistic link function will be used to assess whether differences in classification exist.
The same multivariable model stratified by gender will be used to perform a pre-specified subgroup analysis (re-measuring the echocardiographic LVOT diameter on all subjects who are "re-classified" by CT). This will be done by remeasuring at the traditional LVOT diameter located 5-10 mm below the aortic annulus and also by measuring at the juncture of the aortic leaflets and LVOT in mid-systole (Mayo clinic way). The purpose of this analysis is to determine if the Mayo clinic method of LVOT measurement reduces the number of misclassifications compared to the traditional method. Finally, the investigators will also examine the CT data for threshold values which suggest erroneous or outlier values for echocardiography. Men and women will be assessed separately. For example, a value of 1.6 cm is often found on echocardiography but rarely on CT scanning in their subjective clinical experience.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study is an observational, retrospective review of data collected as standard of care. The study intends to review the charts of up to 400 patients over the last 5 years who underwent both CT and TTE within a one-week timeframe as a workup for aortic valve stenosis at The Heart Hospital Baylor Plano (THHBP) or Baylor University Medical Center (BUMC).
Key inclusion criteria (2 listed)
- Adults over the age of 18.
- Any patient undergoing both TTE and CT scans within a one-week timeframe as a workup for aortic stenosis.
Key exclusion criteria (1 listed)
- There are no specific exclusion criteria for this retrospective review.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Reclassification of patients based on CT measurements of LVOT for AVA and SVI.
Time frame: Baseline
Echocardiography assessments of Aortic stenosis are technician dependent and can vary while CT evaluations are consistent and do not vary by user. This study will retrospectively examine subjects that have undergone both assessments as a workup for definitive aortic valve treatment. The anatomical measurements obtained from CT will be used to recalculate Aortic Valve Area utilizing the standard formulas and gradients/velocities obtained from echocardiography. Patients will be reclassified appropriately into "severe and non-severe" AS according to the new calculations. The results of this will be analyzed to establish standardized ranges for measurements to prevent over or under measuring aortic valve anatomy during these tests (Echo and CT).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2017.
- Individual participant dataSharing planned: No
Related trials for Aortic Valve Stenosis
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Active, not recruitingObservational study
Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
Iliac Disease, Aortic Valve Stenosis
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Recruiting
Exercise and Diet Supplements for Older Patients Undergoing TAVI: the IRON-TAVI Trial
Aortic Stenosis Disease, Aortic Stenosis Symptomatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Paul Grayburn, MD principal investigator
Baylor Research Institute
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aortic Valve Stenosis, run by Baylor Research Institute at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jun 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reclassification of patients based on CT measurements of LVOT for AVA and SVI. (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2017.